Literature DB >> 24928783

Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Jinfei Xu1, Yuwaraj Kadariya1, Mitchell Cheung1, Jianming Pei1, Jacqueline Talarchek1, Eleonora Sementino1, Yinfei Tan1, Craig W Menges1, Kathy Q Cai2, Samuel Litwin3, Hongzhuang Peng4, Jayashree Karar4, Frank J Rauscher4, Joseph R Testa5.   

Abstract

Malignant mesotheliomas are highly aggressive tumors usually caused by exposure to asbestos. Germline-inactivating mutations of BAP1 predispose to mesothelioma and certain other cancers. However, why mesothelioma is the predominate malignancy in some BAP1 families and not others, and whether exposure to asbestos is required for development of mesothelioma in BAP1 mutation carriers are not known. To address these questions experimentally, we generated a Bap1(+/-) knockout mouse model to assess its susceptibility to mesothelioma upon chronic exposure to asbestos. Bap1(+/-) mice exhibited a significantly higher incidence of asbestos-induced mesothelioma than wild-type (WT) littermates (73% vs. 32%, respectively). Furthermore, mesotheliomas arose at an accelerated rate in Bap1(+/-) mice than in WT animals (median survival, 43 weeks vs. 55 weeks after initial exposure, respectively) and showed increased invasiveness and proliferation. No spontaneous mesotheliomas were seen in unexposed Bap1(+/-) mice followed for up to 87 weeks of age. Mesothelioma cells from Bap1(+/-) mice showed biallelic inactivation of Bap1, consistent with its proposed role as a recessive cancer susceptibility gene. Unlike in WT mice, mesotheliomas from Bap1(+/-) mice did not require homozygous loss of Cdkn2a. However, normal mesothelial cells and mesothelioma cells from Bap1(+/-) mice showed downregulation of Rb through a p16(Ink4a)-independent mechanism, suggesting that predisposition of Bap1(+/-) mice to mesothelioma may be facilitated, in part, by cooperation between Bap1 and Rb. Drawing parallels to human disease, these unbiased genetic findings indicate that BAP1 mutation carriers are predisposed to the tumorigenic effects of asbestos and suggest that high penetrance of mesothelioma requires such environmental exposure. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24928783      PMCID: PMC4165574          DOI: 10.1158/0008-5472.CAN-14-1328

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

Authors:  Marjorie G Zauderer; Matthew Bott; Robert McMillan; Camelia S Sima; Valerie Rusch; Lee M Krug; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-11       Impact factor: 15.609

2.  Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations.

Authors:  Thomas Wiesner; Isabella Fried; Peter Ulz; Elvira Stacher; Helmut Popper; Rajmohan Murali; Heinz Kutzner; Sigurd Lax; Freya Smolle-Jüttner; Jochen B Geigl; Michael R Speicher
Journal:  J Clin Oncol       Date:  2012-10-01       Impact factor: 44.544

3.  Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.

Authors:  Yoshie Yoshikawa; Ayuko Sato; Tohru Tsujimura; Mitsuru Emi; Tomonori Morinaga; Kazuya Fukuoka; Shusai Yamada; Aki Murakami; Nobuyuki Kondo; Seiji Matsumoto; Yoshitomo Okumura; Fumihiro Tanaka; Seiki Hasegawa; Takashi Nakano; Tomoko Hashimoto-Tamaoki
Journal:  Cancer Sci       Date:  2012-02-21       Impact factor: 6.716

4.  Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008.

Authors:  S Jane Henley; Theodore C Larson; Manxia Wu; Vinicius C S Antao; Mary Lewis; Germania A Pinheiro; Christie Eheman
Journal:  Int J Occup Environ Health       Date:  2013 Jan-Mar

5.  A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.

Authors:  Karin Wadt; Jiyeon Choi; Joon-Yong Chung; Jens Kiilgaard; Steffen Heegaard; Krzysztof T Drzewiecki; Jeffrey M Trent; Stephen M Hewitt; Nicholas K Hayward; Anne-Marie Gerdes; Kevin M Brown
Journal:  Pigment Cell Melanoma Res       Date:  2012-10-01       Impact factor: 4.693

6.  A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.

Authors:  Megan N Farley; Laura S Schmidt; W Marston Linehan; James Brugarolas; Jessica L Mester; Samuel Pena-Llopis; Andrea Pavia-Jimenez; Alana Christie; Cathy D Vocke; Christopher J Ricketts; James Peterson; Lindsay Middelton; Lisa Kinch; Nick Grishin; Maria J Merino; Adam R Metwalli; Chao Xing; Xian-Jin Xie; Patricia L M Dahia; Charis Eng
Journal:  Mol Cancer Res       Date:  2013-05-24       Impact factor: 5.852

7.  BAP1 and cancer.

Authors:  Michele Carbone; Haining Yang; Harvey I Pass; Thomas Krausz; Joseph R Testa; Giovanni Gaudino
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

Review 8.  Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.

Authors:  Mitchell Cheung; Jacqueline Talarchek; Karen Schindeler; Eduardo Saraiva; Lynette S Penney; Mark Ludman; Joseph R Testa
Journal:  Cancer Genet       Date:  2013-05

9.  Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.

Authors:  Ching-Ni Jenny Njauw; Ivana Kim; Adriano Piris; Michele Gabree; Michael Taylor; Anne Marie Lane; Margaret M DeAngelis; Evangelos Gragoudas; Lyn M Duncan; Hensin Tsao
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

10.  PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.

Authors:  Teruyuki Sato; Atsushi Kaneda; Shingo Tsuji; Takayuki Isagawa; Shogo Yamamoto; Takanori Fujita; Ryota Yamanaka; Yukiko Tanaka; Toshihiro Nukiwa; Victor E Marquez; Yuichi Ishikawa; Masakazu Ichinose; Hiroyuki Aburatani
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more
  49 in total

Review 1.  Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Authors:  Sebastian Walpole; Antonia L Pritchard; Colleen M Cebulla; Robert Pilarski; Meredith Stautberg; Frederick H Davidorf; Arnaud de la Fouchardière; Odile Cabaret; Lisa Golmard; Dominique Stoppa-Lyonnet; Erin Garfield; Ching-Ni Njauw; Mitchell Cheung; Joni A Turunen; Pauliina Repo; Reetta-Stiina Järvinen; Remco van Doorn; Martine J Jager; Gregorius P M Luyten; Marina Marinkovic; Cindy Chau; Miriam Potrony; Veronica Höiom; Hildur Helgadottir; Lorenza Pastorino; William Bruno; Virginia Andreotti; Bruna Dalmasso; Giulia Ciccarese; Paola Queirolo; Luca Mastracci; Karin Wadt; Jens Folke Kiilgaard; Michael R Speicher; Natasha van Poppelen; Emine Kilic; Rana'a T Al-Jamal; Irma Dianzani; Marta Betti; Carsten Bergmann; Sandro Santagata; Sonika Dahiya; Saleem Taibjee; Jo Burke; Nicola Poplawski; Sally J O'Shea; Julia Newton-Bishop; Julian Adlard; David J Adams; Anne-Marie Lane; Ivana Kim; Sonja Klebe; Hilary Racher; J William Harbour; Michael L Nickerson; Rajmohan Murali; Jane M Palmer; Madeleine Howlie; Judith Symmons; Hayley Hamilton; Sunil Warrier; William Glasson; Peter Johansson; Carla Daniela Robles-Espinoza; Raul Ossio; Annelies de Klein; Susana Puig; Paola Ghiorzo; Maartje Nielsen; Tero T Kivelä; Hensin Tsao; Joseph R Testa; Pedram Gerami; Marc-Henri Stern; Brigitte Bressac-de Paillerets; Mohamed H Abdel-Rahman; Nicholas K Hayward
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

2.  Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.

Authors:  Jill A Ohar; Mitchell Cheung; Jacqueline Talarchek; Suzanne E Howard; Timothy D Howard; Mary Hesdorffer; Hongzhuang Peng; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

Review 3.  The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Authors:  Lili Liao; Joseph R Testa; Haifeng Yang
Journal:  Cancer Genet       Date:  2015-02-20

Review 4.  BAP1, a tumor suppressor gene driving malignant mesothelioma.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Transl Lung Cancer Res       Date:  2017-06

5.  Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.

Authors:  Vasiliki Panou; Meghana Gadiraju; Arthur Wolin; Caroline M Weipert; Emily Skarda; Aliya N Husain; Jyoti D Patel; Buerkley Rose; Shannon R Zhang; Madison Weatherly; Viswateja Nelakuditi; Amy Knight Johnson; Maria Helgeson; David Fischer; Arpita Desai; Nanna Sulai; Lauren Ritterhouse; Oluf D Røe; Kiran K Turaga; Dezheng Huo; Jeremy Segal; Sabah Kadri; Zejuan Li; Hedy L Kindler; Jane E Churpek
Journal:  J Clin Oncol       Date:  2018-08-16       Impact factor: 44.544

6.  A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.

Authors:  Patrice Desmeules; Philippe Joubert; Lei Zhang; Hikmat A Al-Ahmadie; Christopher D Fletcher; Efsevia Vakiani; Deborah F Delair; Natasha Rekhtman; Marc Ladanyi; William D Travis; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-07       Impact factor: 6.394

7.  Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.

Authors:  Satu Mäki-Nevala; Virinder Kaur Sarhadi; Aija Knuuttila; Ilari Scheinin; Pekka Ellonen; Sonja Lagström; Mikko Rönty; Eeva Kettunen; Kirsti Husgafvel-Pursiainen; Henrik Wolff; Sakari Knuutila
Journal:  Lung       Date:  2016-02       Impact factor: 2.584

Review 8.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

Review 9.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

Review 10.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.